Yale Cancer Center and the Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill Joins Precision Biologics as Collaborators

Precision Biologics is pleased to announce the addition of both Yale Cancer Center at the Yale School of Medicine and the University of North Carolina at Chapel Hill (UNC) as collaborators on its ongoing Phase 2b clinical trial with its lead therapeutic compound NPC-1C (NEO-102). The randomized, multicenter Phase 2b is currently accruing patients with metastatic pancreatic cancer who have progressed on front line chemotherapy with Folfirinox. The study is combining NPC-1C with second line Gemcitabine and Abraxane chemotherapy. Yale and UNC will be joining the National Cancer Institute, Montefiore-Einstein Medical Center, Rutgers-CINJ, UTSW Medical Center, Washington University in St. Louis, and Duke University Medical Center in partnering with Precision Biologics.

Founded in 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the early detection and treatment of cancer. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials.